- Ignoring the healthy number of product approvals, sexy technologies and encouraging growth prospects, biotech investors continue to head for the exits. The iShares Nasdaq Biotechnology ETF (IBB -2%) has lost almost 13% of its value in less than two weeks. The main culprit appears to be concerns over drug pricing, in the crosshairs of Congress and stoked by presidential candidate Hillary Clinton. Until recently, led by the mess at Valeant Pharmaceuticals (VRX -9.7%), drug makers were driving sales and profits with aggressive price hikes.